Phaseline

Targets › OTC

OTC (Ornithine transcarbamylase, mitochondrial): drug programs, companies and trials

6 programs from 6 companies in 6 trials: 3 Phase 1, 2 Phase 3, 1 Phase 2; Metabolic and endocrine; next expected readout Jun 2027.

Catalyzes the second step of the urea cycle, the condensation of carbamoyl phosphate with L-ornithine to form L-citrulline. The urea cycle ensures the detoxification of ammonia by converting it to urea for excretion. (UniProt, P00480)

Open in Phaseline: the race on OTC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ultragenyx PharmaceuticalDTX301 (avalotcagene ontaparvovec)
AAV8-mediated gene transfer encoding functional OTC
OTCPhase 3OTC DeficiencySep 2027
iECUREECUR-506
Gene editing therapy delivering OTC gene
OTCPhase 3Ornithine Transcarbamylase DeficiencyDec 2027
Arcturus TherapeuticsARCT-810
Ornithine Transcarbamylase (OTC) mRNA in lipid nanoparticle formulation
OTCPhase 2OTC Deficiency–
University College, LondonAAVLK03hOTC
Recombinant AAV-delivered ornithine transcarbamylase gene therapy
OTCPhase 1Ornithine Transcarbamylase DeficiencyJun 2027
CAMP4 TherapeuticsCMP-CPS-001
Antisense oligonucleotide targeting OTC (ornithine transcarbamylase)
OTCPhase 1Healthy VolunteersDec 2027
Rebecca Ahrens-NicklasLNP.UCD.ABE
adenine base editor (ABE) delivered by lipid nanoparticle (LNP) for urea cycle disorder ge
CPS1, OTC, ASS1, ASL, ARG1Phase 1Urea Cycle DisordersSep 2028

Conditions

Ornithine Transcarbamylase Deficiency (2) OTC Deficiency (2) Healthy Volunteers (1) Urea Cycle Disorders (1)

Modalities

other (2), protein or peptide (2), small molecule (1), mixed (1)

Companies

University College, London (1) CAMP4 Therapeutics (1) Rebecca Ahrens-Nicklas (1) Ultragenyx Pharmaceutical (1) Arcturus Therapeutics (1) iECURE (1)

Related targets

CPS1 (1) ASS1 (1) ASL (1) ARG1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.